×h 71 for 7 days), MN (both agents) or P (neither medication). Neurological assessment (ASIA score) was performed by a blinded senior neurologist before treatment and at 1-year follow-up. Early spinal decompression and stabilization was performed as soon as possible after injury. Results: One hundred patients were reassessed at 1 year. Neurological improvement was seen in each group (P50.0001), however no additional neurological bene®t from treatment was observed. Infectious complications occurred more often in patients treated with M. Early surgery (49 patients underwent surgery within 8 h of their accident) did not in¯uence the neurological outcome. The only predictor of the latter was the extent of the spinal injury (complete or incomplete lesion). Conclusion: The present study con®rms the absence of bene®t of pharmacological therapy in this indication. Because of the paucity of clinical studies that demonstrate the ecacy of pharmacological treatment in spinal injury during the acute phase, systematic use of pharmaceutical agents should be reconsidered. Spinal Cord (2000) 38, 71 ± 76
Introduction
The complexity of pathophysiologic mechanisms at play in the immediate aftermath of spinal cord injury explains the diversity of pharmacological protocols that have been tested and suggests that various associations of pharmaceutical agents warrant consideration.
± 11
The initial results concerning neurological improvement after early administration of heavy doses of methyprednisolone to spinal injury victims appeared very promising. 12, 13 However, clinical studies that followed dampened the initial enthusiasm. In France, for example, no pharmacological treatment is currently recommended in this indication. 14 ± 18 The present trial assessed neurological recovery 1 year after administration, within 8 h of spinal-cord injury, of methylprednisolone, nimodipine, or the two combined, in comparison with no pharmacological treatment. The side eects of these treatments and the impact of early spinal surgery on functional recovery were also evaluated.
Patients and Methods
The present prospective randomized was conducted between November 1990 and March 1995 with the consent of the medical ethics committee of our institution. Patients were included only after written consent was obtained from the patient, the patient's family, or both. Inclusion criteria were age older than 15 years and younger than 65 years, and hospitalization within 8 h of vertebral trauma with spinal cord involvement.
Exclusion criteria were a pattern of nerve-root involvement, cauda equina syndrome, open spinal lesions, pregnancy, multiple trauma, head injury with Glasgow score lower than 13, pulmonary contusion, hemodynamic instability that persisted despite volume expansion, mean arterial pressure (MAP) less than 60 mmHg, previous treatment by corticoids or calcium channel blockers, or a history of diabetes mellitus, stomach ulcer, liver failure, or cardiovascular disorders such as high blood pressure or coronary disease. The protocol was discontinued if the patient refused to participate in the study or if the MAP remained lower than 60 mmHg for more than 1 h.
The following data were noted: age, sex, circumstances of the trauma, results of neurological examination at admission and 1 year later according to the classi®cation of the American Spinal Injury Association (ASIA), and the amount of time between the accident and the administration of the treatment. 19 The level of consciousness was evaluated according to the Glasgow coma scale. The injury severity score (ISS) was also recorded. It is based upon the abbreviated injury scale (AIS), which classi®es traumatic lesions according to their nature, location, and severity on a scale of 1 ± 5. 20 The ISS corresponds to the sum of the squares of the highest AIS lesions observed in three of the six regions of the body (head and neck, face, thorax, abdomen and pelvis, extremities and pelvic girdle, and the skin). The maximum possible score is 75. For the patients who necessitated surgery during the ®rst 24 h, the amount of time between the accident and the operation was recorded as was the amount of intraoperative bleeding. Complications were noted, including metabolic (hyperglycemia), infectious (pneumonia, septicemia, urinary tract infections), cardiovascular and digestive disorders. The duration of assisted ventilation and that of the overall hospital stay were recorded.
Plain anteroposterior and lateral ®lms of the spine were obtained for all patients. Spinal computed tomography (CT), CT myelography, or magnetic resonance imaging was obtained as needed.
The neurological examination at admission and 1 year later were carried out by a senior neurologist who was blind with respect to the treatment administered to the patient as was the orthopedic surgeon who managed the patient. This examination was performed in the emergency room within the ®rst few hours following admission and before any surgery. Patients meeting the inclusion criteria were randomly separated into four groups, each of which received a dierent treatment. Group M received methylprednisolone at a dose of 30 mg×kg 71 over 1 h, followed by 5.4 mg×kg 71 ×h 71 for 23 h, Group N received nimodipine at a dose of 0.15 mg×kg 71 ×h 71 for 2 h followed by 0.03 mg×kg 71 × h 71 for 7 days. Group MN received both methylprednisolone and nimodipine at the same doses used in groups M and N; and patients in group P received neither medication. The designation of a patient to a group was decided using a random selection cycle that started over after every series of eight subjects to yield groups that were balanced in number.
Results for the quantitative values that concerned all the patients are expressed as mean+standard deviation. The quantitative values for each group are expressed as median and are provided with the 25th to 75th percentile range. The statistical analysis was carried out using chi2, Fisher, or Kruskal-Wallis nonparametric tests as appropriate. The eect of treatment upon the outcome at 1 year according to the complete or incomplete nature of the spinal cord lesion and the usefulness of early spinal surgery were evaluated using two-way analysis of variance; P50.05 was considered to be signi®cant.
Results
Between November 1990 and March 1995, 106 patients, including 48 paraplegic patients and 58 tetraplegic patients were included in this study. Fortyeight patients (45%) had complete cord lesions. Ninety per cent of the patients were men. Motor vehicle accidents were the most frequent (46%) cause of spinal cord trauma, followed by falls (29%) and sports accidents, predominantly diving accidents (25%). The four groups had no signi®cant dierences with respect to age, initial Glasgow score, ISS, or delay between trauma and the administration of treatment (Table 1) . There were also no signi®cant dierences among the groups in terms of initial ASIA motor scores (ASIAmO), pinprick sensation scores (ASIAsO), or pain scores (ASIApO) ( Table 2) .
Neurological examination after one year was possible in 100 of the patients. Five patients died within 1 year of their accident. One paraplegic patient died due to pulmonary embolism in the early aftermath of the accident. Two tetraplegic patients (47 years old and 65 years old) died from septicemia and multiorgan failure. One paraplegic patient committed suicide, and one tetraplegic patient succumbed to respiratory failure following a second (25 ± 25) 4 (3 ± 6)
The values are expressed as average with the 25th and 75th percentile in parentheses. ISS=injury severity score
Medication for acute spinal cord injury V Pointillart et al motor vehicle accident. One patient refused to come back for a 1 year follow-up examination. In all four groups, there was a signi®cant improvement in neurological scores at 1 year (P50.0001), regarding ASIA motor, sensibility, and pain scores (ASIAm1, ASIAs1, and ASIAp1) ( Table 2) . At 1 year, there were no signi®cant dierences among the four groups in terms of any of the ASIA scores. Two-way analysis of variance showed no interaction between methylprednisolone and nimodipine. Only the complete or incomplete nature of the spinal cord lesion was correlated with sublesional recovery (P50.0001). Sixty-®ve patients, most of whom (72%) were tetraplegic, were cared for in a traumatologic intensive care unit. The analysis of infectious, cardiovascular, metabolic, and gastrointestinal complications concerned only these patients. Although the incidence of infectious complications was higher in the patients who received methylprednisolone (66% versus 45%), this dierence was not signi®cant (Table 3) . Two patients treated with methylprednisolone had a bleeding gastroduodenal ulcer that required only medical treatment. Thirteen of the patients in intensive care (representing all four groups) experienced episodes of bradycardia of less than 40 beats min 71 . No patient was excluded due to persistent arterial hypotension (MAP560 mmHg). Hyperglycemia occurred in 16 out of 35 patients treated with methylprednisolone (46%) as compared to only one out of 30 patients who did not receive methylprednisolone (3%) and this dierence was signi®cant (Table 4 ). These cases of hyperglycemia appeared early necessitating intravenous administration of insulin, but did not last longer than 3 days. Although motor recovery was less complete in the patients who were treated with methylprednisolone and who initially developed hyperglycemia (ASIAml: 56 versus 62), the dierence was not signi®cant. Overall, these various complications aected neither the duration of stay in the intensive care unit nor that of mechanically assisted ventilation (Table 4) .
Eighty patients (76%) underwent surgery within 24 h of the accident (average interval of time, 7.5+4.2 h). Among these patients, 49 (61%) were 
Discussion
The complexity and multiplicity of the pathophysiologic mechanisms involved in the aftermath of a spinalcord injury, explains to a large degree the diversity of experimental pharmaceutical approaches to this disorder. 11 Nonetheless, three lines of research are currently in the forefront: lipid peroxidation inhibitors, calcium channel blockers, and more recently, antagonists of N-methyl-D-aspartate receptors, which mediate the neurotoxic eects of glutamate. In contrast, there have been few published clinical trials. At present, the only one that has had an impact on the management of spinal-cord injuries is the NASCIS II study. 12, 13 Unfortunately, only moderate progress has been made, and it is reasonable to assume that, given the diversity of the pathophysiologic phenomena, use of more than one medication might enhance this progress.
In the present trial, the neurological status of the patients was improved at the 1-year follow-up visit in all four groups. Only patients with a normal state of consciousness were included in the study to avoid potential underestimation of the initial ASIA scores related to patients' inability to cooperate. Consequently, the validity of the observed improvement after 1 year is a reliable ®nding. In the patients with complete spinal-cord injury, this improvement, when present, involved the level of the lesion and the two adjacent caudal levels to various degrees. The greatest amelioration was noted in the patients who had incomplete cord lesions. In contrast with the ®ndings NASCIS II, there was no dierence in the improvement of the patients who received methylprednisolone compared to that of those who received no speci®c treatment. Similarly, the administration of nimodipine or the methylprednisolone-nimodipine combination had no in¯uence on neurological recovery in comparison with that of the control group. These results must be interpreted with caution since the number of patients in each group may have been insucient. However, even though the absence of interaction between methylprednisolone and nimodipine enabled us to double the number of patients in the two groups that received one of the two agents (52 patients M+, 48 patients M7, 51 patients N+, and 49 patients N7), no signi®cant dierence or tendency was found. The present results obtained with methylprednisolone con®rmed those of several recently published clinical trials. 14, 18 However, comparison of the latter results and the present ®ndings is not straightforward for two reasons. Since 1991 in the United States the administration of methylprednisolone has become a standard procedure in the management of spinal cord injury, even though the Food and Drug Administration has not yet authorized its use in this indication. Methylprednisolone has not been authorized for marketing in this indication in France either. 11 Consequently, the most recent studies are retrospective. The second obstacle to comparing studies is the absence of consensual terminology in the initial neurological evaluation. The currently recommended scores proposed by the ASIA allow a very precise analysis of spinal cord involvement, but the use of ASIA scores is not yet widespread. Moreover, their determination requires full patient cooperation. Nonetheless, functional recovery of patients treated by corticoids has been reported to be similar to that of patients who did not receive corticoids regardless of the scales or classi®cations of recovery that were used.
In the present trial, nimodipine was used for the ®rst time in this indication in humans. Ischemia is a ®nal mechanism common to most spinal cord lesions and vascular changes are directly involved in this process. In several experimental models of spinal cord injury, the early administration of nimodipine reduced the drop in spinal cord blood¯ow in the proximity of the lesion compared to placebo, but the bene®t in terms of neurological recovery remains to be demonstrated. 2 ± 6 The current patients showed good hemodynamic tolerance for nimodipine, probably because of the systematic preliminary volume resuscitation. At 1 year, neurological improvement was not signi®cantly dierent from that of the methylprednisolone group or controls. Maintaining MAP above 60 mmHg may be insucient. Studies in which the minimum MAP is 70 mmHg, or perhaps even 80 mmHg might be warranted, regardless of the pharmacological approach.
The incidence of infectious complications was higher among patients treated with corticoids (66% versus 45%). This tendency has been observed in other studies. 14, 18 The action of corticoids on the immune system is well known, but their direct responsibility should be tempered. 21, 22 Over the last few years, complex interactions among the immune system, central nervous system and endocrine system have been discovered. Patients with a neurological dysfunction have been shown to have a de®cient lymphocyte response and impaired natural killer cytotoxic activity, which would at least partially explain their increased susceptibility to infection. 23 In the present series the rate of pulmonary disorders was similar in the groups M+ and M7. The neurological level of the cord injury is certainly one of the elements that should be considered among factors predisposing to pulmonary complications. In our series there was no signi®cant dierence among the four groups in the level of neurological lesions.
Even more surprising is the absence elsewhere 12, 13, 24 of metabolic complications, in particular of hyperglycemia in view of the fact that 31% of the present M+ patients had severe, but transient hyperglycemia. The role of hyperglycemia in the exacerbation of ischemic lesions is still the subject of debate. 25, 26 In the M+ group neurological recovery was poorer in the patients who had initial hyperglycemia, even though no patient had deterioration at the level of the initial neurological lesion. Consequently, early detection and treatment of this complication is probably warranted. These metabolic and infectious complications aected neither the average duration of stay in intensive care nor that of mechanical ventilation and they should not be considered as an obstacle to the use of a medication if its therapeutic eectiveness is demonstrated.
The usefulness of early surgery remains in the forefront of the treatment of spinal-cord injury. It has been shown experimentally that the persistence of spinal cord compression is correlated with neurological worsening. 27, 28 Furthermore, an unstable vertebral lesion presents a risk of secondary displacement. Although there is relative consensus concerning the need for surgery of patients who have spinal injury with incomplete neurological de®cit, in complete lesions the type and timing of surgical intervention are unsettled issues. 29 ± 31 In the present study, the neurological improvement of the patients who underwent surgery within 8 h of the spinal cord injury was not signi®cantly dierent from that of those who had later or no surgical treatment. An insucient number of patients might explain this result. Given the importance of osteosynthesis in reducing the risks of microtrauma to the nervous tissue, facilitating patient care, and preventing complications of the decubitus position and secondary spinal deformations that hamper rehabilitation, the authors advocate this technique in most cases of complete spinal lesions. Neither the pharmacological approach, nor early surgery in¯uenced functional recovery in the present series. The complete or incomplete nature of the primary spinal-cord lesion was the only factor that was correlated with functional recovery.
Conclusion
In contrast with previous ®ndings in the literature, 12 the present authors found no bene®t from the early use of methylprednisolone in spinal-cord injuries. Nimodipine, which was tested for the ®rst time in this indication, was also ineective. Early decompression with osteosynthesis failed to in¯uence neurological recovery. The only factor correlated with neurological recovery was the complete or incomplete nature of the initial spinal-cord lesion. A precise assessment of motor and sensory de®cits such as that proposed by the ASIA, is an essential prerequisite for pharmacological studies of such patients. Methylprednisolone, nimodipine, or both failed to alter the course of spinal-cord injury and their use in this indication should be reconsidered.
